Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Undergraduate Medical Student Research Programs Research Abstract Proposal Proposed ResearchTitle: Program BScMed Date: 9/8/15 The art of preventing broken hearts in colorectal and renal cell cancer Proposed Research - Abstract (250 word maximum) Colorectal and renal cell cancer are major public health concerns in Canada. An increased understanding of the biology of cancer has allowed for the development of new and effective therapies which utilize various pathways to suppress tumor growth. Two types of targeted therapy currently in use include monoclonal antibodies (Bevacizumab; BVZ) and tyrosine kinase inhibitors (Sunitinib; SNT). An unexpected consequence of the use of these two anti-cancer drugs, however, is the development of cardiotoxicity in nearly 25% of colorectal (CRC) and renal cell cancer (RCC) patients. In the emerging field of Cardio-Oncology, specialized collaborative efforts amongst Cardiologists and Oncologists are developing in multiple academic centers across Canada, including the University of Manitoba, to address the cardiotoxic side effects of anti-cancer drugs. Serial monitoring of left ventricular ejection fraction (LVEF) using noninvasive cardiac imaging is the single most important clinical diagnostic tool in the recognition of cardiac dysfunction in cancer patients. Once symptomatic heart failure develops in the setting of a reduced LVEF, however, irreversible cardiac injury may have potentially occurred in this cancer population. Although novel cardiac imaging techniques including tissue velocity and strain imaging using echocardiography are able to detect early evidence of left ventricular systolic dysfunction due to anti-cancer drugs, the more important clinical question is whether the prophylactic administration of cardioprotective agents can prevent cardiac injury from developing at the onset. Currently, there are no known therapies approved for the prevention of cardiotoxicity in the CRC and RCC populations. This innovative research proposal will be the first study of its kind to explore whether the prophylactic administration of renin-angiotensin system (RAS) antagonists can prevent BVZ and/or SNT mediated cardiotoxicity in a murine model. Please include a brief description of the student's role The BSc Med student will be exposed to animal models of chemotherapy mediated cardiotoxicity, acquisition and analysis of murine echocardiograms, histological analysis using light and electron microscopy, protein studies, and statistical analysis. Contact Information: Name: Dr. Davinder S. Jassal MD, FACC, FRCPC Address: Y3531-Bergen Cardiac Care Centre, St. Boniface General Hospital Phone: 204-237-2023 Email: [email protected] PRINT SUBMIT SAVE